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Abstract
Neurite plasticity is a critical aspect of brain functional recovery after stroke. Emerging data
suggest that Ras-related C3 botulinum toxin substrate 1 (Rac1) plays a central role in axonal
regeneration in the injured brain, specifically by stimulating neuronal intrinsic growth and
counteracting the growth inhibitory signaling that leads to growth cone collapse. Therefore, we
investigated the functional role of Rac1 in axonal regeneration after stroke.
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Delayed treatment with a specific Rac1 inhibitor, NSC 23766, worsened functional recovery,
which was assessed by the pellet reaching test from day 14 to day 28 after stroke. It additionally
reduced axonal density in the peri-infarct zone, assessed 28 days after stroke, with no effect on
brain cavity size or on the number of newly formed cells. Accordingly, Rac1 overexpression using
lentivirus promoted axonal regeneration and functional recovery after stroke from day 14 to day
28. Rac1 inhibition led to inactivation of pro-regenerative molecules, including mitogen-activated
protein kinase kinase (p-MEK)1/2, LIM domain kinase (LIMK)1, and extracellular signalregulated kinase (p-ERK)1/2 at 14 days after stroke. Inhibition ofRac1 reduced axonal length and
number in cultured primary mouse cortical neurons using microfluidic chambers after oxygenglucose deprivation (OGD) without affecting cell viability. In contrast, inhibition of Rac1
increased levels of glial fibrillary acidic protein, an extrinsic inhibitory signal for axonal growth,
after stroke in vivo and in primary astrocytes after OGD.
In conclusion, Rac1 signaling enhances axonal regeneration and improve post-stroke functional
recovery in experimental models of stroke.
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Introduction
Stroke is the primary cause of adult long-term disability in both the USA and worldwide [1].
Although the mortality rate of stroke is decreasing, the incidence of stroke is rising, which
translates into an increasing prevalence of patients living with persistent disability [2].
Mounting evidence suggests that axonal outgrowth is a critical aspect of functional recovery
because it is essential for establishing new neural connections to compensate for the strokeinduced loss of function. Thus, targeting this process has emerged as an alternative and
potentially more tractable target to reduce long-term disability after stroke [3]. However,
after injury, this axonal regrowth and remodeling in the adult mammalian central nervous
system (CNS) is limited, partially because there is a lack of robust activation of intrinsic
neuronal properties for outgrowth, but also because the extrinsic glial environment, such as
glial scar formation, inhibits axonal regeneration.
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Ras-related C3 botulinum toxin substrate 1 (Rac1) is a Rho-related small GTPase that plays
a critical role in axonal growth during neuronal development [4]. Rac1 is ubiquitously
expressed throughout the brain [5]. However, Rac1 becomes inactivated when bound to
guanosine diphosphate (GDP) and activated when bound to guanosine triphosphate (GTP).
Interestingly, emerging data suggest a critical role of the Rac1 pathway in axonal
regeneration in the injured brain, but no studies have investigated whether Rac1 is a viable
target for axonal regeneration after cerebral ischemia. Downstream substrates of Rac1
(ERK1/2, GFAP, i.e.) are implicated in the stimulation of neuronal intrinsic outgrowth
properties, as well as counteracting the glial extrinsic environment, which represent the two
critical components that govern axonal plasticity in injured brain. In cultured mouse cortical
neurons, Rac1 is required for atorvastatin-induced neurite plasticity after glutamate-induced
neuronal excitotoxicity [6]. Interestingly, Rac1 levels are increased in peri-infarct regions in
rats after stroke, and this elevation persists for 2 weeks after stroke during the critical phase
of axonal regeneration and recovery [7]. Therefore, we investigated the functional role of
Rac1 in axonal regeneration and its mechanisms in the recovery phase after stroke in mice.

Methods
Animals
The study was approved by the Center for Laboratory Animal Care of the University of
Connecticut Health Center and University of Texas Health Science Center, and performed
following the National Institutes of Health Guide for the Care and Use of Laboratory
Animals. The C57BL/6J WT male mice (7–8 weeks) were from Charles River.
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Middle Cerebral Artery Occlusion (MCAO)
MCAO procedure has been described in details previously [8, 9]. Briefly, after a skin
incision along the midline of the mouse neck, 90-min MCA occlusion was induced in mice
using an intraluminal filament. After occlusion, mice were reperfused by suture withdrawal
and then sacrificed 14 or 28 days later. Mice of the sham groups underwent the same
procedure as those in the stroke groups, but without occluding the MCA.
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Histological Assessment
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Brain atrophy measurement was analyzed as previously described [9, 10]. Generally, mice
were perfused and fixed with 4% paraformaldehyde 28 days after stroke. The fixed brains
were then sliced for cresyl violet staining in accordance with previously published
procedures [10,11]. The brain tissue loss was determined following this calculation: % brain
tissue lost = 100% × [(contralateral hemisphere area - contralateral ventricular area) (ipsilateral hemisphere area - ipsilateral ventricular area)]/(contralateral hemisphere area contralateral ventricular area).
Production of Lentiviral Vector
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Lentiviral vectors carrying Rac1 and GFP were generated following the procedures
described in our previous publications [12]. The concentrations of the lentivirus were 109
transducing units/mL, which was titered by transducing 293FT cells and counting eGFPpositive colonies [12]. For virus titering, briefly, 293FT cells were cultured on a 24-well
plate and lentivirus were added to wells. The eGFP fluorescence was visualized under a
fluorescent microscope after incubation. To determine the titer of lentivirus, the overall
fraction of cells that were eGFP positive in each well was calculated, multiplied by the
corresponding total cell number in each well, then divided by the actual volume of added
lentivirus.
Lentivirus Administration In Vivo
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Lentiviral vectors encoding Rac1 or GFP were injected into the mouse brains following
previously established methods [12]. Briefly, a four-point injection was carried out at the
following coordinates: 0.5 mm anterior to the bregma, 2.0 or 3.0 mm lateral (right) to the
sagittal suture, and 1.0 or 2.8 mm from the surface of the skull [12]. A total of 1 μL of
concentrated lentivirus (109 transducing units/mL) was injected into each position at a rate
of 0.5 μL/min with a 30-gauge needle on a 10-μL Hamilton syringe (catalog no. 80010).
After the lentivirus was injected, the needle remained in position for 10 min before it was
withdrawn. This injection protocol causes minimal damage to the brain tissue according to
our previous experience and is accounted for by control groups injected with GFP virus [12].
Drug Administration In Vivo and In Vitro
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For in vivo studies, Rac1 inhibitor, NSC23766 (NSC), was administrated daily from days 7
to 13 after stroke (7 days, 4.0 mg/kg, i.p.). Control mice received the equal amount of
vehicle. While most of the published work used 2.5 mg/kg/day in mice [13, 14], we chose
4.0 mg/kg/day to ensure an effective inhibition and found no evidence for toxicity at this
dose. For in vitro experiments, the concentration of 30 μM NSC was used [15]. BrdU
(bromodeoxyuridine) was injected 7 days after stroke (dose, 50 mg/kg, i.p./8 h for 24 h)
[16].
Behavior Measurements Using Pellet Reaching Test
Pellet reaching is a well-organized movement involving complex neural control systems.
This test has the capability to measure both the motor and sensory functions of the impaired
limb and is increasingly used in long-term survival studies for stroke recovery [17–19]. As
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previously described, the success rate of pellet reaching was calculated according to the
following equation (number of successful reaches/total number of reaches × 100). Mice
were pre-tested to assess and control for individual differences. All studies were conducted
and analyzed by blinded investigators.
Oxygen-Glucose Deprivation (OGD) in Primary Cortical Neurons and Astrocytes
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To assess the role of Rac1 in the intrinsic capacity of neurons for axonal outgrowth, we used
mouse primary neuronal culture system, where there is no/minimal glial influence. To
measure outgrowth, we utilized a microfluidic chamber which separates axons from
neuronal soma and permits direct axonal outgrowth monitoring in cortical neurons [20].
Cortical neurons were challenged by OGD for 2 h [21]. Twenty-four hours after OGD, the
cells were co-cultured with 30 μM NSC until 96 h after OGD. Axonal elongation and
numbers were then analyzed by NFL staining at 96 h after OGD, as others have shown
significant axonal regeneration induced by OGD at this time point [20]. Elongating axons
were imaged with a fluorescence microscope. The number of axons were counted and the
length of each axon was measured by manually tracing each individual axon with ImageJ
software. Primary astrocytes were challenged by OGD for 2 h. Twenty-four hours after
OGD, the cells were co-cultured with 30 μM NSC until 96 h after OGD.
Western Blot Analysis
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Western blot procedures were performed as previously described [1, 23]. For in vivo studies,
GFAP, p-LIMK 1, p-ERK1/2, and p-MEK1/2 were analyzed in the brain samples harvested
14 days after stroke. Rac1 in mouse brain was detected 7 days after injection of Rac1 or GFP
vectors. For in vitro experiments, glial fibrillary acid protein (GFAP) expression in primary
astrocytes after OGD was probed. β-Actin or β-tubulin was employed as a loading control.
The integrated optical density (IOD) of each band was measured using ImageJ. The IOD
results were normalized by dividing each value by the mean IOD of the control groups.
Immunohistochemistry and Data Quantification

Author Manuscript

The staining method was described in previous publications [1, 22]. The Neurofilament-L
(NFL) and GFAP were stained in mouse brain slices 28 days after stroke. After staining, the
images were recorded and analyzed using a Zeiss Axiovert 200M microscope (Carl Zeiss,
Oberkochen, Germany) with an X-Cite 120Q fluorescence illumination system (Lumen
Dynamics Group Inc., Mississauga, ON, Canada) and Zeiss image acquisition software
(Zeiss LSM 510). Identical digital imaging acquisition parameters were used throughout the
study. NFL or GFAP were semi-quantified as the integrated optical density (IOD) of greenpositive signals in the penumbra of the ischemic hemisphere using ImageJ. The IOD results
were normalized by dividing each value by the mean IOD of the control groups.
Statistical Analyses
Data are presented as the mean ± standard error of the mean (SEM). Mean comparisons
between the experimental groups were analyzed by one-way or two-way analysis of variance
(ANOVA) followed by post hoc tests for multiple comparisons when appropriate. P <0.05
was considered statistically significant by using SPSS 19 software (Chicago, IL, USA). Both
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behavioral and histological assessments were performed by an investigator blinded to the
vectors/drug treatment.

Results
Delayed Inhibition of Rac1 Led to Poorer Functional Recovery and Reduced Axonal
Density

Author Manuscript

A specific Rac1 inhibitor, NSC23766 (NSC), or vehicle (saline) was administrated to WT
mice starting 7 days after MCAO and injected once daily for 7 days (4.0 mg/kg/day). We
tested functional motor deficits at 28 days after stroke onset by performing the pellet
reaching test. Stroke produced consistent deficits in the pellet reaching test, and gradual
recovery was observed in vehicle-treated stroke mice. We found that the delayed inhibition
of Rac1 with NSC significantly worsened functional recovery from day 14 to day 28 after
stroke (day 28, vehicle 0.39 ± 0.03 vs. NSC 0.18 ± 0.03, n = 7–9, *p < 0.05; Fig. 1a).
We then studied the effect of delayed Rac1 inhibition in axonal density in the peri-infarct
zone. We found that Rac1 inhibitor treatment significantly reduced axonal density
(neurofilament staining, NFL) in the peri-infarct zone, assessed at 28 days after stroke
(vehicle 1.00 ± 0.12 vs. NSC 0.50 ± 0.04, n = 4, *p < 0.05; Fig. 1b).
Delayed Rac1 Inhibition Did Not Increase Tissue Loss or Reduce the Number of BrdUPositive Cells
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It remains possible that Rac1 inhibition affects brain injury, which would contribute to the
changes in functional outcome and axonal density seen in our experiments. The likelihood is
slim as NSC was started at 7 days after stroke, when the infarct growth is complete.
Regardless, we performed CV staining at 28 days after stroke to examine infarction (cavity
size). No differences (vehicle 34.2 ± 4.3% vs. NSC 31.26 ± 3.4%, n = 7–9/group, p > 0.05;
Fig. 1c, e) were seen between vehicle and NSC-treated groups. Rac1 has been implicated in
neurogenesis, which could potentially contribute to changes in axonal density. To measure
neurogenesis, we injected BrdU to label proliferating cells in the brain 7 days after stroke
and stained for BrdU-positive cells 28 days after stroke. No difference in BrdU staining in
the peri-infarct zone was observed between the vehicle-treated and NSC-treated groups
(vehicle 1.00 ± 0.37 vs. NSC 1.00 ± 0.18, n = 4, p > 0.05;Fig. 1d).
Delayed Overexpression of Rac1 Improved Functional Recovery and Increased Axonal
Density after Stroke

Author Manuscript

We next studied how Rac1 affects stroke recovery by overexpressing Rac1 using a lentiviral
vector carrying the Rac1 gene. We injected highly concentrated lentivirus encoding WT
Rac1 at 7 days after stroke into both the cortex and striatum. We found that delayed
overexpression of Rac1 improved functional recovery, as assessed by the pellet reaching test
from day 14 to day 28 after stroke (day 28, LV-GFP 0.34 ± 0.02 vs. LV-Rac1 0.51 ± 0.04, n
= 8, *p < 0.05; Fig. 2a). Axonal density was also significantly increased in the peri-infarct
zone in the group with Rac1 overexpression (data LV-GFP 1.00 ± 0.08 vs. LV-Rac1 1.67
± 0.10, *p<0.05, n = 4, Fig. 2b).
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The in vivo effect of the lentivirus on protein expression was confirmed by western blot. To
assess this, vectors were injected into both the cortex and striatum in mice at 7 days after
stroke. One week after the injection, western blot analysis demonstrated a consistent
increase in levels of Rac1 protein in the stroke hemisphere (LV-GFP 1.00 ± 0.11 vs. LVRac1 1.53 ± 0.11, n = 4, *p < 0.05; Fig. 2c).
Rac1 Inhibition Reduced P-LIMK 1, P-MEK1/2, and P-ERK1/2 In Vivo
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We then moved on to study the mechanisms of Rac1 in stimulating axonal regeneration after
stroke. MEK1/2 and ERK1/2 are well-known pro-regenerative molecules, as they stimulate
the expression of pro-regenerative genes. Importantly, Rac1 is known to activate MEK (via
PAK1), which then phosphorylates ERK. Additionally, Rac1 also targets LIMK1, another
potent enhancer of axonal plasticity [22–24]. As expected, we found that delayed inhibition
of Rac1 reduced the levels of p-LIMK 1 (day 14, vehicle 1.47 ± 0.09 vs. NSC 0.75 ± 0.12, n
= 4, #p < 0.05; Fig. 3a), p-MEK1/2 (day 14, vehicle 2.07 ± 0.17 vs. NSC 1.29 ± 0.19, n = 4,
#p < 0.05; Fig. 3b), and p-ERK1/2 (day 14, vehicle 2.42 ± 0.35 vs. NSC 0.79 ± 0.19, n = 4,
#p < 0.05; Fig. 3c).
Inhibition of Rac1 Reduced Axonal Length and Number after OGD
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We then examined the effect of Rac1 inhibitor (NSC) on axonal outgrowth by using a
microfluidic chamber to separate axons from neuronal soma. At 6 days in vitro, cortical
neurons were challenged by OGD for 2 h and then co-cultured with 30 μM NSC for 96 h,
and axonal elongation was analyzed by immunocytochemical staining of NFL. Rac1
inhibitor significantly suppressed axonal outgrowth both in length (OGD control 309.76
± 51.79 μm vs. OGD plus NSC 143.95 ± 28.78 μm, *p < 0.05, n = 4; Fig. 4a) and in axon
numbers after OGD (OGD control 15.33 ± 2.33 vs. OGD plus NSC 30 μM 6.33 ± 1.20, *p <
0.05; Fig. 4b).
At this dosing regimen, NSC incubation had no effect on cortical neuron’s cell viability in
vitro (OGD + vehicle 60.3 ± 2.8% vs. OGD + NSC 58.92 ± 3.2%, p > 0.05; Fig. 4c).
Inhibition of Rac1 Increased GFAP after Stroke In Vivo and in Primary Astrocytes after
OGD

Author Manuscript

We hypothesized that Rac1 also enhances axonal regeneration by counteracting the growth
inhibitory signaling (e.g., glial scar) that leads to growth cone collapse, providing an
additional mechanism for improved functional recovery after stroke. Our data showed that
GFAP, a marker for glial scar formation and a signal of axonal growth inhibition, had
elevated expression in the ischemic hemisphere at 28 days after stroke (Fig. 5a).
Furthermore, we observed that the Rac1 inhibitor treated cohort had upregulated levels of
GFAP at 14 days after stroke (day 14, vehicle 1.00 ± 0.24 vs. NSC 1.66 ± 0.11, n = 4, *p <
0.05; Fig. 5b).
Finally, we then confirmed the effects of Rac1 on GFAP in primary astrocytes after OGD. In
line with the in vivo data, we demonstrated that inhibition of Rac1 increased the level of
GFAP in astrocytes at 96 h after OGD (vehicle 1.45 ± 0.06 vs. NSC 2.22 ± 0.15, n = 4, #p <
0.05; Fig. 5c).
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Discussion
In the present study, we demonstrated that Rac1 plays vital roles in brain plasticity and
functional recovery after experimental stroke. Specifically, we have made the following
significant findings: (1) Rac1 inhibition led to poorer functional recovery after stroke in
long-term survival and reduced axonal density in the penumbra. This treatment did not cause
changes in either the brain cavity size or the number of newly divided cells, suggesting that
outgrowth of existing neurons is the major contributor to changes in axonal density
following treatment. (2) Overexpression of Rac1 promoted improvement of motor and
sensory functions, increased long-term survival, and also increased axonal density. (3) Rac1
inhibition reduced the activation of pro-regenerative molecules such as ERK and MEK. (4)
Treatment with Rac1 inhibitor exacerbated GFAP expression in vivo and in vitro after
stroke, potentially also contributing to reduced axonal outgrowth.
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The weak intrinsic growth capacity in neurons and the inhibitory factors from extrinsic glial
environments are among the major causes of regenerative failure in the CNS after injury [25,
26]. Rac1 promotes axonal regeneration by counteracting the glial inhibitory signal to axon
growth. Rac1 signaling can reduce glial scar formation, a major physical and chemical
barrier for axonal growth following stroke [27]. Mounting evidence shows that glial
inhibitory signals are the major cause of growth cone collapse and limited CNS axonal
regeneration. Reactive astrocytes are the primary contributors of the formation of glial scar,
which is a major physical and chemical barrier for axonal outgrowth following injury.
Chondroitin sulfate proteoglycans (CSPGs), secreted by the astrocytic scar, are highly
inhibitory to regeneration after stroke, and decreased CSPG contributes to improved
plasticity in stroke. Secreted CSPG inhibits axonal growth by binding specific receptors
expressed on the growth cone membrane, causing the cone to collapse and ultimately
leading to axonal retraction. In spinal cord injury models, animals treated with constitutively
active Rac1 showed significantly lower expression of GFAP and CSPGs than untreated
controls [28]. In line with this report, our study demonstrated that Rac1 inhibition
exacerbated GFAP signaling in the brain after stroke using both in vivo and in vitro models.
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Our work additionally showed that Rac1 stimulates the intrinsic capacity of neurons for
axonal outgrowth. Rac1 upregulates the extracellular signal-regulated kinase (ERK)
pathway, which is well known to induce axonal regeneration in the injured central nervous
system [29, 30]. This pathway consists of three kinases: rapidly accelerated fibrosarcoma
(Raf), mitogen-activated protein/extracellular signal-regulated kinase (MEK), and ERK.
Pak1, the downstream target of Rac1, phosphorylates Raf, which then phosphorylates MEK,
which in turn phosphorylates ERK [29]. Importantly, ERK1/2 mediates the transcriptional
activation of regeneration-associated genes (RAGS). This can occur either directly, when
phosphorylated ERK1/2 (p-ERK1/2) translocates from the cytoplasm to the nucleus, or
indirectly, when p-ERK1/2 phosphorylates downstream kinases in the cytoplasm which
subsequently enter the nucleus [31, 32]. For example, ERK phosphorylates cyclic adenosine
monophosphate response element binding protein (CREB). When phosphorylated, CREB
induces the transcription of genes important for axonal plasticity processes after CNS injury,
such as growth-associated protein 43 (GAP43) [26]. Our work suggests that Rac1 and
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MEK/ERK interact with each other, although a causative relationship needs to be
investigated in the future.
ERK1/2 activation in neurons stimulates pro-regenerative gene expression. However,
activation of ERK1/2 in astrocytes may also stimulate gliosis, which would paradoxically
hinder axonal regeneration. This effect could be minimal in stroke, as our IHC showed pERK1/2 was mostly confined to neuronal cells at 28 days after stroke (data not shown),
indicating that ERK1/2 signaling is selectively activated in neurons during the chronic phase
of stroke.
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Interestingly, the literature shows that Rac1 is pro-regenerative after brain injury; however,
other studies have shown that Rac1 inhibition may also provide neuroprotection and reduce
injury in the acute phase of injury [33]. To minimize potential effects on acute injury size,
we deliberately started Rac1 intervention (both Rac1 inhibitor and lentiviral overexpression)
at 7 days after the onset of stroke. This allowed us to hone in on studying the role of Rac1 in
brain plasticity. In general, 7 days post-stroke is beyond the window for neuronal protection
in this model, as stroke infarction completes within a week after MCA occlusion [34].
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One caveat of this study is that axonal regeneration is influenced by factors that can be
produced by the peripheral system, such as IL-1 and TGF-beta, as these cytokines affect
glial scar formation [35]. Rac1 is also an important mediator of immunity, and inhibition of
Rac1 in peripheral blood mononuclear cells from human blood was shown to reduce IL-1
beta release [36]. Although manipulation of Rac1 provides considerable evidence for a
combined effect of both central and peripheral responses, brain injection of lentivirus may
not allow us to observe peripheral effects. We will closely monitor changes in cytokines
using peripheral blood samples. This approach will also help to evaluate the possible role of
Rac1 in post-stroke inflammation, as Rac1 is known to participate in the immune response
[37, 38].
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The translational significance of our findings is high, as we identified a molecule that plays
critical roles in enhancing brain plasticity and functional recovery after stroke. Our
experiments significantly improved our understanding of the complex axonal growth
program that is activated after stroke. Given that the economic burden of post-stroke
disability will continue to increase as the population ages and acute stroke care improves,
developing novel drugs to improve functional recovery is a growing and urgent public health
need. Currently, the only pharmacological treatment for stroke is tissue plasminogen
activator (tPA) [2], which has a short therapeutic window, leaving no effective treatment
available for the majority of stroke patients. A weak intrinsic regenerative potential in
neurons and inhibition from glial cells are major causes of limited axonal regeneration after
stroke. Here, we identified a target molecule that stimulates intrinsic components of
neuronal growth capacity and simultaneously reduces glial inhibition. Therefore, targeting
this molecule may offer robust improvements in functional recovery after stroke. It is
especially important in the elderly, the population at greatest risk of stroke, as we have
shown an increased astrogliosis occurs in aged individuals after stroke, which is associated
with worse recovery in animal models [11].

Transl Stroke Res. Author manuscript; available in PMC 2019 October 01.

Liu et al.

Page 9

Author Manuscript

In summary, we newly demonstrated a critical role of Rac1 in promoting axonal
regeneration and brain remodeling after experimental stroke. Our work suggests that Rac1
targets the two key components in axonal rewiring in the post-ischemic brain, both by
enhancing the intrinsic properties of neurons to extend axons, as well as by inhibiting glial
scar formation in the chronic recovery phase after experimental stroke. Our study suggests
that Rac1 signaling is a potential therapeutic target for promoting brain remapping and
functional recovery after stroke.
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Fig. 1.
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Delayed inhibition of Rac1 led to poorer recovery and reduced axonal density after stroke. a
Functional recovery assessed by pellet reaching test from day 14 to day 28 after stroke. N =
7–9, *p < 0.05. b Axonal density (neurofilament staining)in the peri-infarct zone was
assessed on 28 days after stroke. Scale bars: 10 μm. N =4,*p < 0.05. c NSC treatment did not
affect tissue loss 28 days after stroke. N =7–9, p > 0.05. d NSC treatment did not reduce
BrdU-positive cells at 28 days after stroke. N =4, p > 0.05. e An illustration of how
quantification of brain tissue loss was performed after stroke using CV staining. % brain
tissue lost = 100% × [(contralateral hemisphere area - contralateral ventricular area) (ipsilateral hemisphere area - ipsilateral ventricular area)]/(contralateral hemisphere area contralateral ventricular area). Red area: ipsilateral hemisphere area; yellow area: ipsilateral
ventricular area; purple area: contralateral hemisphere area; blue area: contralateral
ventricular area. A specific Rac1 inhibitor, NSC23766 (NSC), or vehicle (saline) was
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administrated to WT mice starting 7 days after MCAO and injected once daily for 7 days
(4.0 mg/kg/day). Data were as mean ± SEM
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Overexpression of Rac1 improved functional recovery and increased axonal density after
stroke. a Functional recovery assessed by pellet reaching test from day 14 to day 28 after
stroke. N =8, *p < 0.05. b Axonaldensity (neurofilament staining)in the peri-infarct zone
was assessed on 28 days after stroke. Scale bars: 10 μm. N =4,*p < 0.05. c Rac1 lentivector
significantly increased Rac1 protein levels 7 days after injection in vivo. N =4, *p <0.05. We
injected highly concentrated lentivirus encoding WT Rac1 1 week after stroke into both the
cortex and striatum. Data were as mean ± SEM
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Rac1 inhibition reduced p-LIMK 1, P-MEK1/2, and p-ERK1/2 in vivo. A specific Rac1
inhibitor, NSC, or vehicle (saline) was administrated to WT mice starting 7 days after
MCAO and injected once daily for 7 days (4.0 mg/kg/day). Samples collected 14 days after
stroke. a p-LIMK 1; b p-MEK1/2; c p-ERK1/2. N =4, *p < 0.05 for comparison between
sham and stroke group injected with vehicle; #p < 0.05 for comparison between vehicle and
NSC group under stroke condition. Data were as mean ± SEM
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Inhibition of Rac1 reduced axonal length and numbers after OGD. Microfluidic chamber
was used to separate axons from neuronal soma. At 6 days in vitro, cortical neurons cocultured with 30 μM NSC23766 for 96 h after challenged by OGD for 2 h, axonal length (a)
and number (b) were analyzed by immunocytochemistry NFL staining. N = 4, *p < 0.05.
Scale bars: 50 μm. c NSC incubation had no effect on cortical neuron’s cell viability. N =4, p
> 0.05. Data were presented as mean ± SEM
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Fig. 5.

Inhibition of Rac 1 increased levels of GFAP in vivo and in cultured astrocytes after stroke.
a GFAP is highly expressed in brains 28 days after stroke. Scale bars: 1 mm. b Rac1
inhibitor upregulated GFAP expression in mice 14 days after stroke. A specific Rac1
inhibitor, NSC, or vehicle (saline) was administrated to WT mice starting 7 days after
MCAO and injected once daily for 7 days (4.0 mg/kg/day). N =4, *p <0.05. c Rac1 inhibitor
increased levels of GFAP in primary astrocytes after OGD. Cells were challenged by OGD
for 2 h. 24 h after OGD, the cells were co-cultured with 30 μM NSC for a total of 96 h. N
=4, *p < 0.05 for comparison between sham and OGD group treated with vehicle, #p < 0.05
for comparison between vehicle and NSC group under OGD condition. Data were presented
as mean ± SEM
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